Browse DNER

Summary
SymbolDNER
Namedelta/notch-like EGF repeat containing
Aliases UNQ26; bet; H_NH0150O02.1; WUGSC:H_NH0150O02.1; delta-notch-like EGF repeat-containing transmembrane; Delta ......
Chromosomal Location2q36.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell membrane; Single-pass type I membrane protein. Note=Present on the membrane of dendrites and cell bodies but excluded from axonal membrane. Also found in early endosomes in the somatodendritic region (By similarity).
Domain PF00008 EGF-like domain
PF12661 Human growth factor-like EGF
Function

Activator of the NOTCH1 pathway. May mediate neuron-glia interaction during astrocytogenesis (By similarity).

> Gene Ontology
 
Biological Process GO:0001764 neuron migration
GO:0007219 Notch signaling pathway
GO:0007220 Notch receptor processing
GO:0007416 synapse assembly
GO:0007517 muscle organ development
GO:0007519 skeletal muscle tissue development
GO:0010001 glial cell differentiation
GO:0014706 striated muscle tissue development
GO:0014902 myotube differentiation
GO:0014904 myotube cell development
GO:0042063 gliogenesis
GO:0042692 muscle cell differentiation
GO:0048741 skeletal muscle fiber development
GO:0048747 muscle fiber development
GO:0050808 synapse organization
GO:0051146 striated muscle cell differentiation
GO:0055001 muscle cell development
GO:0055002 striated muscle cell development
GO:0060537 muscle tissue development
GO:0060538 skeletal muscle organ development
Molecular Function GO:0005112 Notch binding
GO:0030276 clathrin binding
Cellular Component GO:0005769 early endosome
GO:0030425 dendrite
GO:0043025 neuronal cell body
GO:0044297 cell body
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-2122948: Activated NOTCH1 Transmits Signal to the Nucleus
R-HSA-162582: Signal Transduction
R-HSA-157118: Signaling by NOTCH
R-HSA-1980143: Signaling by NOTCH1
Summary
SymbolDNER
Namedelta/notch-like EGF repeat containing
Aliases UNQ26; bet; H_NH0150O02.1; WUGSC:H_NH0150O02.1; delta-notch-like EGF repeat-containing transmembrane; Delta ......
Chromosomal Location2q36.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between DNER and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between DNER and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
24935874Hodgkin lymphomaInhibit immunityTransfection of HEK293T and Hela cells to express DNER coupled to an enhanced green fluorescent protein tag using a plasmid previously used to detect human DNER antibodies. We also confirm that DNER is the target antigen of the anti-Tr immune response.
29650805melanomaInhibit immunityWe show that BET proteins are overexpressed in NRAS-mutant melanoma and that high levels of the BET family member BRD4 are associated with poor patient survival.
Summary
SymbolDNER
Namedelta/notch-like EGF repeat containing
Aliases UNQ26; bet; H_NH0150O02.1; WUGSC:H_NH0150O02.1; delta-notch-like EGF repeat-containing transmembrane; Delta ......
Chromosomal Location2q36.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of DNER in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolDNER
Namedelta/notch-like EGF repeat containing
Aliases UNQ26; bet; H_NH0150O02.1; WUGSC:H_NH0150O02.1; delta-notch-like EGF repeat-containing transmembrane; Delta ......
Chromosomal Location2q36.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of DNER in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.270.722
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.5910.624
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.9080.383
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.5570.298
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.0440.971
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 471.2010.388
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.6340.469
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.7770.581
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11121.9720.146
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.1870.88
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.3640.825
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.4260.256
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of DNER in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14177.15.91.21
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1031033.3-23.30.423
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.72.711
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.73.40.31
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.85.9-1.11
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.79.1-1.41
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.1011.10.36
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47250250.364
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.63.7-1.11
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.57.7-3.21
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolDNER
Namedelta/notch-like EGF repeat containing
Aliases UNQ26; bet; H_NH0150O02.1; WUGSC:H_NH0150O02.1; delta-notch-like EGF repeat-containing transmembrane; Delta ......
Chromosomal Location2q36.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of DNER. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolDNER
Namedelta/notch-like EGF repeat containing
Aliases UNQ26; bet; H_NH0150O02.1; WUGSC:H_NH0150O02.1; delta-notch-like EGF repeat-containing transmembrane; Delta ......
Chromosomal Location2q36.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of DNER. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by DNER.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolDNER
Namedelta/notch-like EGF repeat containing
Aliases UNQ26; bet; H_NH0150O02.1; WUGSC:H_NH0150O02.1; delta-notch-like EGF repeat-containing transmembrane; Delta ......
Chromosomal Location2q36.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of DNER. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolDNER
Namedelta/notch-like EGF repeat containing
Aliases UNQ26; bet; H_NH0150O02.1; WUGSC:H_NH0150O02.1; delta-notch-like EGF repeat-containing transmembrane; Delta ......
Chromosomal Location2q36.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of DNER expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolDNER
Namedelta/notch-like EGF repeat containing
Aliases UNQ26; bet; H_NH0150O02.1; WUGSC:H_NH0150O02.1; delta-notch-like EGF repeat-containing transmembrane; Delta ......
Chromosomal Location2q36.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between DNER and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolDNER
Namedelta/notch-like EGF repeat containing
Aliases UNQ26; bet; H_NH0150O02.1; WUGSC:H_NH0150O02.1; delta-notch-like EGF repeat-containing transmembrane; Delta ......
Chromosomal Location2q36.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting DNER collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.